Logo

OACC

Oaktree Acquisition Corp. III Life Sciences

OACC

Oaktree Acquisition Corp. III Life Sciences • NASDAQ
$10.56 ▼ -0.05% (-0.01)
Market Cap $259.86 M
52w High $10.85
52w Low $9.95
Dividend Yield 0%
P/E 0
Volume 3.14K
Outstanding Shares 24.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $225.579K ▼ $1.967M ▲ 0% $0.08 ▲ $0 ▲
Q2-2025 $0 $269.81K ▼ $1.874M ▲ 0% $0.076 ▲ $-269.81K ▼
Q1-2025 $0 $444.802K ▲ $1.659M ▲ 0% $0.068 ▲ $1.659M ▲
Q4-2024 $0 $303.711K ▲ $1.38M ▲ 0% $0.056 ▲ $-303.711K ▼
Q3-2024 $0 $48.095K $-48.095K 0% $-0.002 $-48.095K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.329M ▼ $201.25M ▲ $8.246M ▲ $-6.765M ▼
Q2-2025 $1.385M ▲ $199.176M ▲ $8.138M ▲ $191.038M ▲
Q1-2025 $1.281M ▼ $197.241M ▲ $8.077M ▲ $189.163M ▲
Q4-2024 $1.357M ▲ $195.251M ▲ $7.746M ▲ $187.505M ▲
Q3-2024 $0 $638.992K $662.087K $-23.095K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $1.967M ▼ $-56.518K ▲ $191.99M ▲ $-193.437M ▼ $-56.518K ▼ $-56.515K ▲
Q2-2025 $2.153M ▲ $-131.998K ▼ $250K ▲ $0 ▼ $28.315K ▼ $-131.998K ▼
Q4-2024 $1.38M ▲ $-89.687K ▼ $-191.99M ▼ $193.437M ▲ $1.357M ▲ $-89.687K ▼
Q3-2024 $-48.095K $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement OACC is essentially a “blank check” company, so its income statement is very simple. It has no real operating business yet, no sales, and no ongoing operating expenses beyond basic SPAC costs. Any small profit you see is likely from interest on cash held in trust rather than from a normal business. In practical terms, there is no underlying revenue engine to analyze until a merger target is announced and combined financials are available.

Balance Sheet

Balance Sheet The balance sheet is mostly cash and short-term assets associated with its SPAC structure, with little to no traditional operating assets like plants, equipment, or inventory. Debt appears minimal or nonexistent, and equity is largely the capital raised for a future deal. Financial health at this stage is less about profitability and more about how carefully that cash is preserved and how efficiently it is used when a life sciences target is chosen.

Cash Flow

Cash Flow Cash flows are not driven by a business model yet. Most movements in cash come from financing activities—money raised in the SPAC and routine costs of staying public. There is essentially no meaningful cash from operations and no investment in long-term assets yet. The real cash flow story will only start once OACC completes a merger and the operating company’s cash generation, spending, and funding needs become visible.

Competitive Edge

Competitive Edge Right now, OACC competes with other SPACs and traditional IPO routes to attract a high-quality life sciences company. Its main advantages are the Oaktree sponsor brand, prior experience taking healthcare companies public, and a clear focus on innovative biopharma, medical devices, and related areas. However, it has no products, customers, or market share of its own. Its competitive position will be defined almost entirely by the quality and differentiation of the company it eventually merges with, and by the terms of that deal.

Innovation and R&D

Innovation and R&D OACC does not conduct research or develop products itself. All future innovation and R&D capacity will come from the life sciences company it acquires. The strategy is to find a target with strong pipelines, scalable science or technology platforms, and a capable management team. Past Oaktree SPAC deals in telehealth and biosimilars suggest a preference for companies that use technology to expand access, reduce costs, or disrupt existing healthcare models, but for now any discussion of R&D strength is purely about intentions, not current activity inside OACC.

Summary

OACC is a newly listed, pre-merger SPAC built as a vehicle to take a life sciences company public, not a functioning operating business. Its current financials are intentionally simple: no revenue, mainly cash on the balance sheet, and small income items tied to its cash holdings and structure. The real story—and the real risks and opportunities—will appear only once a merger partner is announced. At that point, attention shifts from the SPAC shell to the target’s products, competitive landscape, R&D depth, regulatory exposure, and ability to turn scientific assets into sustainable cash flows. Until then, assessment is largely about the sponsor’s track record and the eventual deal terms, rather than about OACC’s standalone performance.